
|Videos|August 25, 2021
RVL Pharmaceuticals: Shifting toward ocular aesthetics
Author(s)David Hutton, Alex Delaney-Gesing
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Advertisement
JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sharper vision starts here
2
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION
3
iOpeners: Zubair Ansari, MD, shares his global health journey with Nicole Bajic, MD
4
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
5